Distributor inventory
Voglibose 0.2 mg + Metformin Hydrochloride 1000 mg (Extended Release) tablets
Type 2 diabetes mellitus: to improve blood glucose control in adults when diet and exercise are insufficient; helps reduce post-meal (postprandial) and fasting blood sugar.
Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, lowering post-meal glucose spikes. Metformin (ER) reduces glucose production in the liver and improves insulin sensitivity, helping lower fasting and overall blood sugar.
Take exactly as prescribed. Usually taken with meals; voglibose works best when taken just before/with the first bite of food. Swallow the extended-release tablet whole; do not crush or chew. Regularly monitor blood glucose as advised.
Common side effects of VOGLIMAC GM 1 HD may include:
For prescription use only. Metformin may rarely cause lactic acidosis—risk increases with severe kidney disease, dehydration, heavy alcohol use, severe infection, shock, or hypoxia; kidney function should be assessed before and during therapy. Temporarily stop metformin before/after iodinated contrast procedures and major surgery as advised by doctor. Use caution in liver disease, heart failure, and elderly. Risk of hypoglycaemia increases when used with insulin or sulfonylureas; recognize symptoms and treat promptly.
